Related Experiment Video
Updated: Jun 25, 2025
Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
Published on: March 20, 2020
Nanoparticle-Mediated Immunotherapy in Triple-Negative Breast Cancer
Ruoyi Wang1, Xu Huang1, Xiaoxi Chen1
1Department of Breast Surgery, The Second Norman Bethune Hospital of Jilin University, Changchun 130021, P.R.C.
Abstract:
Triple-negative breast cancer (TNBC) is an aggressive subtype with the worst prognosis and highest recurrence rates. The treatment choices are limited due to the scarcity of endocrine and HER2 targets, except for chemotherapy. However, the side effects of chemotherapy restrict its long-term usage. Immunotherapy shows potential as a promising therapeutic strategy, such as inducing immunogenic cell death, immune checkpoint therapy, and immune adjuvant therapy. Nanotechnology offers unique advantages in the field of immunotherapy, such as improved delivery and targeted release of immunotherapeutic agents and enhanced bioavailability of immunomodulators. As well as the potential for combination therapy synergistically enhanced by nanocarriers. Nanoparticles-based combined application of multiple immunotherapies is designed to take the tactics of enhancing immunogenicity and reversing immunosuppression. Moreover, the increasing abundance of biomedical materials holds more promise for the development of this field. This review summarizes the advances in the field of nanoparticle-mediated immunotherapy in terms of both immune strategies for treatment and the development of biomaterials and presents challenges and hopes for the future.
Insights
Triple-negative breast cancer (TNBC) immunotherapy shows promise using nanotechnology. Nanoparticles enhance drug delivery and combination therapies, offering new hope against this aggressive cancer.
Area of Science:
- Oncology
- Nanotechnology
- Immunotherapy
Background:
- Triple-negative breast cancer (TNBC) is aggressive with limited treatment options beyond chemotherapy.
- Chemotherapy's side effects limit its long-term use in TNBC.
- Immunotherapy presents a promising alternative strategy for TNBC treatment.
Purpose of the Study:
- To review advances in nanoparticle-mediated immunotherapy for TNBC.
- To explore immune strategies and biomaterial development in this field.
- To discuss future challenges and opportunities in TNBC immunotherapy.
Main Methods:
- Review of current research on nanoparticle-mediated immunotherapies.
- Analysis of nanoparticle applications in enhancing immunogenicity and reversing immunosuppression.
- Examination of biomaterial advancements for immunotherapy delivery.
Main Results:
- Nanotechnology improves delivery, targeting, and bioavailability of immunotherapeutic agents.
- Nanoparticle-based combination therapies show synergistic potential.
- Biomaterials offer enhanced possibilities for developing novel immunotherapies.
Conclusions:
- Nanoparticle-mediated immunotherapy is a rapidly advancing field for TNBC.
- Combination strategies leveraging nanotechnology hold significant therapeutic promise.
- Continued development in biomaterials and immune strategies is crucial for future progress.
